Evidence map›Paper›PMID 21123367›Full record

ArticleNeuro-oncology2011

AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor.

Juinn-Lin Liu, Zhenyu Mao, Gary E Gallick, W K Alfred Yung

Open access · bronzeAbstract read
In one paragraph

Article in Neuro-oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Novel functional roles of caspase-related genes in the regulation of apoptosis and autophagy.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2016
    Article
  9. Article
  10. Article
  11. Nongenomic Mechanisms of PTEN Regulation.International journal of cell biology · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Juinn-Lin LiuBrain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Zhenyu Mao
Gary E Gallick
W K Alfred Yung
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
DIFFERENTIALLY EXPRESSED GENE PRODUCTS IN HUMAN GLIOMASR01CA056041 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YUNG, W K ALFRED · 1992 to 2007
$2.3M
DIFFERENTIALLY EXPRESSED GENE PRODUCTS IN HUMAN GLIOMASR55CA056041 · NCI · UNIVERSITY OF TEXAS MD ANDERSON CAN CTR · PI STECK, PETER A · 1991 to 1991
–
NCI NIH HHS CA16672NCI NIH HHS CA56041NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA056041
6 · The paper itself

Abstract

The regulation of the subcellular localization of phosphatase and tensin homologue (PTEN) is critical to its tumor-suppressing functions. Previously, we found that the activation of the phosphoinositide 3-kinase (PI3K)/Akt/mTOR/S6 protein kinase (S6K) cascade triggers the nuclear export of PTEN during the G1/S transition. Because mTOR can be alternatively downregulated by tuberous sclerosis complex 2 (TSC2) activation mediated by 5' adenosine monophosphate-activated protein kinase (AMPK), we proposed that the activation of AMPK α1/2 by LKB1 and/or by calmodulin-dependent protein kinase kinase (CaMKK) would also block the nuclear export of PTEN in a manner similar to that of inhibitors of PI3K, mTOR, and S6K. We found that in LKB1-null A549 lung adenocarcinoma cells, an AMPK activator, metformin, failed to block the nuclear export of PTEN, and the reintroduction of functional LKB1 into these cells restored the metformin-mediated inhibition of the nuclear export of PTEN. In addition, the nuclear export of PTEN was blocked in cells treated with the CaMKK activator ATP, and this inhibition was reversed by the addition of inhibitors of either AMPK (compound C) or CaMKK (STO-609). Although the nuclear export of PTEN is blocked by metformin in MCF-7 breast cancer cells carrying wild-type LKB1, this inhibition could not be reversed by an AMPK inhibitor, suggesting that LKB1 could regulate the nuclear export of PTEN by bypassing AMPK α1/2. Moreover, ATP could not block the nuclear export of PTEN in AMPK α1/2(-/-) or TSC2(-/-) mouse embryonic fibroblasts. However, metformin was still able to induce the LKB1-mediated inhibition of the nuclear export of PTEN in these cells. Taken together, these findings strongly suggest that although CaMKK mediates the nuclear retention of PTEN mainly through the activation of AMPK, LKB1 can regulate the nuclear-cytoplasmic trafficking of PTEN, with or without the AMPK/TSC2/mTOR/S6K-signaling intermediates.

Indexed as

Active Transport, Cell NucleusAdenocarcinomaAMP-Activated Protein Kinase KinasesAMP-Activated Protein KinasesBlotting, WesternBreast NeoplasmsFemaleFluorescent Antibody Technique, IndirectHumansHypoglycemic AgentsImmunoenzyme TechniquesLung NeoplasmsMetforminProtein Serine-Threonine KinasesPTEN PhosphohydrolaseTOR Serine-Threonine KinasesAMP-Activated Protein Kinase KinasesAMP-Activated Protein KinasesHypoglycemic AgentsMetforminMTOR protein, humanPRKAA1 protein, humanPRKAA2 protein, humanProtein Serine-Threonine KinasesPTEN PhosphohydrolasePTEN protein, humanSTK11 protein, humanTOR Serine-Threonine KinasesTSC2 protein, humanTsc2 protein, mouseTuberous Sclerosis Complex 2 ProteinTumor Suppressor Proteins

Identifiers

PMID21123367
PMCPMC3064623
OpenAlexW2160551242

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.